Search the Newsreel

Canaccord reitera su calificación de Hims & Hers tras superar previsiones en el Q2

Hims & Hers Q2 2026 earnings: loss despite revenue beat

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million. The company raised its full-year …

The Technical Signals Behind (HIMS) That Institutions Follow

The article analyzes Hims & Hers Health Inc. (HIMS) using AI models to identify technical signals and institutional trading strategies. It highlights a near-term strong sentiment for HIMS that could challenge persistent mid and long-term weakness, noting resistance testing and a significant risk-reward short …

Hims & Hers anticipates $880M-$900M Q3 revenue while raising 2026 outlook to $3.1B-$3.3B

Earnings Call Insights: Hims & Hers Health (HIMS) Q2 2026 MANAGEMENT VIEW * "In the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people." (Co-Founder, Chairman & CEO Andrew Dudum) * "In June, we became …

Hims & Hers Health Inc (HIMS) (Q2 2026) Earnings Call Highlights: Revenue Surges 40% to ...

This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International …

HIMS Stock Tumbles As Branded GLP-1 Pivot Triggers Margin Hit And One-Time Charges

Hims & Hers Health Q2 Earnings Call Highlights

This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International …

Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Misses Estimates By $0.32 EPS

Earnings call transcript: Hims & Hers Q2 2026 revenue beats, EPS misses

Informe de resultados de Hims & Hers: ingresos del Q2 2026 superan previsiones, pero el BPA defrauda

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. …

Hims & Hers Lowers Profit Forecast, Shares Drop

Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close." View Comments

Hims Hers Health earnings missed by $0.32, revenue topped estimates

Hims & Hers Shares Drop After Beating Revenue Forecast With $753 Million, Margins Narrow

Hims Topples As Obesity Kingpin Hits A Snag On Weighty Second-Quarter Loss

Hims stock fell late Monday after its second-quarter loss came in bigger than expected, upsetting a sales beat. Continue Reading

Hims & Hers shares fall after second-quarter wider-than-expected loss

Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%. The company reported a loss of 37 cents per share, compared with analysts' estimate of a loss of 5 cents per share. Revenue rose 38% year …

Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss

Hims & Hers Health (NYSE: HIMS) grows revenue but posts sizable loss on deals

Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops

Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next …

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026 Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026 Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to …

Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Hims & Hers Health, Inc. announced strong financial results for Q2 2026, with revenue up 38% year-over-year to $753 million and subscribers growing to nearly 2.9 million. The company raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion and updated its …

HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

RADNOR, Pa., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who …

Hims & Hers Health (HIMS) Responds To FTC Lawsuit Over Patient Data Use

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices …

Hims & Hers Health (HIMS) Launches AI Weight Loss Care, Is It Still A Bargain?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Hims & Hers Health (HIMS) just introduced an AI powered care experience for Hers weight loss members, including a connected smart scale and app …

HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Hims & Hers and would like to discuss your legal …

Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2026 results on Aug. 10, after the closing bell. In the last reported quarter, the company's loss per share of 18 cents lagged the Zacks Consensus Estimate of earnings per share of 4 …

Noticias de acciones de Hims & Hers Health Inc (HIMS)

Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of an Ongoing Investigation Into Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Hims & Hers Health, Inc. following a lawsuit filed by the FTC and California/Utah consumer protection agencies. The lawsuit alleges that Hims & Hers failed to clearly disclose prescription charges, made it …

HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney

Kirby McInerney LLP has announced an investigation into potential securities fraud against Hims & Hers Health, Inc. following a lawsuit filed by the Federal Trade Commission (FTC). The FTC accused Hims of sharing customers’ medical information with third-party advertisers, specifically Meta Platforms, leading to …

Pilgrims Pride stock hits 52-week low at 26.48 USD By Investing.com

Pilgrim's Pride stock has dropped to a 52-week low of $26.50, marking a 42.4% decline over the past year. This comes after the company reported disappointing Q2 2026 results, missing analyst expectations for both earnings and revenue due to lower chicken prices and legal …

Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Hims & Hers Health, Inc. (HIMS) after the Federal Trade Commission (FTC) filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news on July …

Weekly Recap: Hims & Hers data-sharing suit and FDA panel backs peptides

Hims & Hers (HIMS) is facing lawsuits from the FTC, Los Angeles County, and Utah over alleged data-sharing with Meta and Snap, as well as deceptive billing practices. Simultaneously, the company is exploring opportunities in the peptides market after an FDA advisory panel recommended …

NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news, HIMS's …

Crimson Tide hails return to profit following “period of significant change”